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Abstract There is excess breast cancer mortality for African-Americans (AA) compared to
European-Americans (EA) of 1.5e2.2 fold that first appeared in 1970s and has been worsening
since. This disparity may not be explained solely by reduced access to medical care. We
proposed that surgery to remove a primary tumor induces angiogenesis of distant dormant
micrometastases in 20% of premenopausal node-positive patients. This hypothesis helps
explain the reduced benefit of mammography for women aged 40e49. Interestingly, for AA
the average age at diagnosis is 46 while for EA it is 57. The resultant increased proportion
of AA premenopausal breast cancer suggests a possible explanation for the AA/EA excess mor-
tality. Early detection, which began in the 1970s, is more effective in postmenopausal women
than in premenopausal women. Since AA breast cancer is mostly premenopausal and EA breast
cancer is mostly postmenopausal, it might be anticipated that starting in the 1970s because of
surgery-induced early mortality, outcome would be superior for EA compared to AA.
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Analysis of a mature breast cancer database of 1173 early
stage patients led us to propose that surgery to remove
a primary tumor can result in acceleration of metastasis
development by inducing proliferation of quiescent singleshed by Elsevier Ltd. All rights reserved.
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The latter phenomenon is clinically significant in approxi-
mately 20% of premenopausal women with node-positive
disease.1e3 This proposed surgery-induced angiogenesis is
associated with node positive patients compared to node
negative patients by a ratio of 5:1 and premenopausal
patients compared to postmenopausal patients by a ratio
of 2:1.
The proposed mechanisms are growth factors produced
in response to wounding and also the removal of the
primary, as occurs in animal models where the primary
exerts homeostatic effects (e.g. by angiogenesis inhibi-
tors). Most of these relapses occur within 10 months of
surgery for patients untreated with adjuvant therapy and
result in a surge in mortality at 2e3 years.
While this mechanism is well documented in experimen-
tal systems, there is not yet direct evidence that it occurs
in breast cancer. However, the necessary elements of this
mechanism, (1) a bimodal hazard of relapse, (2) long-term
dormancy of breast cancer and (3) a transient surge of
proangiogenic and growth factors post surgery, have been
described in a number of other studies.4e24
We have reported that this surgery-induced early surge
in breast cancer mortality could explain the mammography
paradox, a counterintuitive excess mortality in the first
6e8 years after starting screening in randomized trials to
determine the value of early detection for women aged
40e49. This effect is not apparent for women aged 50e59.
In long-term follow-up, the expected advantage of early
detection eventually appears in both age groups although it
remains difficult to exclude the possibility that the younger
cohort are benefiting by incident screening episodes once
they have passed the menopause. According to our calcula-
tions, surgery-induced angiogenesis would produce 0.1
deaths per 1000 young women 2e3 years after the start
of screening. Both the magnitude and timing of the early
mortality surge agree with data from randomized clinical
trials conducted in several countries and over some decades
of time.
Suggestions about the racial connection
This information was presented in the September 2005 issue
of the International Journal of Surgery25 and triggered sev-
eral letters to the editor. Two of these letters have caused
us to investigate whether this effect might also have rele-
vance to the reported difference in breast cancer outcome
for black women compared to white women. That is the
subject of this hypothesis essay.
A letter from one of us (I.G.), a clinician treating breast
cancer in Africa, pointed out that surgery-induced angio-
genesis might explain the very high early mortality and also
the generally poor outcome of patients in that part of the
world.26 Also noted was that African patients typically pres-
ent to clinics in their early 40s, and a high percentage have
node-positive status and locally advanced disease. It is
common for an African woman to first seek alternative
treatment after detecting a lump due to fears of ‘‘pro-
voking’’ the tumor. Often after palliative surgery and
chemotherapy there is unexplained very rapid disease
progression.27,28The other letter that focused our attention was from an
African-American (AA) attorney who informed us that it is
a commonly held belief by AA women that ‘‘cancer spreads
when the air hits it’’ or words to that effect.29 This attorney
suggested that what we described might provide a scientific
explanation for that belief.
The ‘‘cancer spreads when the air hits it’’ notion is
believed by 61% of AA and 29% of European Americans
(EA).30 It has some similarity to the ‘‘provoking’’ that Afri-
can women associate with conventional treatment. The
‘‘air hits it’’ myth is frequently dismissed as a superstitious
fable with no scientific foundation and also has been asso-
ciated with belief systems of persons of ‘‘low socioeco-
nomic status’’.31
Myths seldom lack any connection with reality. Could it
be that AA believe in the myth twice as frequently as EA
because they observe it twice as often? Is it possible that
the effect we found in the all-white (Milan) database is
amplified somehow in AA and especially Africans?
Data from epidemiology
Anderson, Jatoi and colleagues32,33 have studied the sub-
ject of the AA excess mortality compared to EA. There is
a mortality disadvantage of 1.5e2.2 fold that first appeared
in US Surveillance Epidemiology and End Results (SEER) data
in the mid 1970s and has been widening since.32e36 As mam-
mographic early detection first started in the mid 1970s and
has been more and more widely used since then, re-
searchers suggested a connection between the two events.
An initial hypothesis was that the mortality disparity was
explainable based on a two-tiered access to medical care in
the US. This hypothesis was tested by analyzing the racial
disparity within the US Department of Defense (DoD),
where everyone including spouses has equal access to
free medical care. Two papers published in 2003 examined
this and came to different conclusions. One paper said
equal access to early detection would eliminate the
mortality difference36 and the other reported that racial
disparity in mortality has been widening even in the DoD
system,33 so one cannot easily dismiss the problem as re-
duced access to medical care. Other biology-based factors
should be investigated.
Interestingly, epidemiological data show that at less
than age 57, AA have higher mortality from breast cancer
compared to EA, but over age 57, that relationship is
actually reversed.32 Moreover, it is important to observe
that the age that breast cancer is diagnosed differs be-
tween AA and EA women. For AA, the average age of pre-
sentation is 46 while it is 57 for EA. So AA breast cancer is
mainly premenopausal while EA breast cancer is mainly
postmenopausal. Other ethnicities also have different
peak incidental ages. For US Hispanics, the average age
of presentation is 50 years.36 As mentioned, in Africa the
median age is the early 40s. For Jordanian women, the av-
erage age is the middle 40s.37 There is a wide range among
Asian-Americans. Filipino- and Hawaiian-American women
most frequently are diagnosed between age 21 and 49 while
Japanese- and Chinese-American women are most fre-
quently diagnosed age 50e59 and 60e69, respectively.38
This information is listed in Table 1.
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In the light of our findings, we suggest a possible partial
explanation of the racial disparity as follows. Since early
detection is apparently more effective in postmenopausal
women than in premenopausal women and AA breast cancer
is basically premenopausal while EA breast cancer is post-
menopausal, it may be expected that starting in the 1970s,
mortality will be superior for EA compared to AA. This would
mean that early detection protocols, which were tested and
optimized mainly on white women both in the US and Europe
(most trials were in Sweden), may be suboptimal for AA
women among others and especially for African women.
We do not intend to oversimplify this subject, but it
seems clear to us that at least part of the phenomenon of
widening mortality difference between AA and EA in the
United States can be explained on the assumption of
surgery-induced metastasis acceleration (mainly the an-
giogenesis-driven acceleration) for premenopausal node-
positive breast cancer patients. This also might provide
a partial explanation of why breast cancer outcome in
Africa is so often unfavorable.
Moreover, it should also be considered that breast
cancer is influenced by the hormone milieu of the host
woman, mainly in premenopause. Indeed, breast cancer
sex hormone receptor-content that is a main factor pre-
dicting outcome, varies during each menstrual cycle39 as
does vascular endothelial growth factor (VEGF) content.40
Differences between AA and EA women have been re-
ported. Luteal phase estradiol levels are higher in AA
women than in EA women.41,42 AA women undergo menar-
che earlier than EA women.43 AA also tend to cycle more
rapidly than their Caucasian counterparts.44 Each of these
differences in the cycle and its hormones could contribute
to outcome differences, especially since it is reported that
the outcome of premenopausal breast cancer also depends
upon the hormonal milieu as reflected by the menstrual
cycle phase at the time of its resection.45
Suggested tests of hypothesis
The most obvious test of the hypothesis would be a direct
investigation of the mortality pattern following the ex novo
Table 1 The age at which breast cancer is diagnosed
varies among the various racial and ethnic groups as
indicated
Racial/Ethnic group Age at which breast cancer
is diagnosed
European-Americans Average: 57 years
African-Americans Average: 46 years
Africans (Nigeria) Average: early 40s
Hispanic-Americans Average: 40s
Jordanians Average: 50 years
Hawaiian-Americans Mode:21e49 years
Filipinos Mode:21e49 years
Chinese-Americans Mode: 50e59 years
Japanese-Americans Mode: 60e69 years
These data have been reported in slightly different formats.introduction of mammography screening in a not previously
screened mixed population. The comparison of mortality
rates among the four subsets (blackdno mammography;
whitedno mammography; blackdmammography; whited
mammography) would provide the most persuasive answer
to the question.
Lacking this direct (and unrealistic) comparison, we
should pursue some less direct clues. As the main factor
resulting in early recurrence and death for premenopausal
patients is proposed to be the angiogenesis switch of
avascular micrometastases, according to the hypothesis,
we suggest to focus tests keying upon this biology. Three
research areas could be investigated: microvessel density,
angiogenesis inhibition, and genetic polymorphism.
Microvessel density
Angiogenesis assessment in invasive breast cancer formalin-
fixed paraffin-embedded specimens to study microvessel
densities using monoclonal antibodies to CD31, CD34 and
human factor VIII related antigen (FVIIIRAg) have been
found to be significantly associated with patient survival
(PZ 0.008, PZ 0.0014 and PZ 0.007, respectively).46 The
level of neovascularization in a tumor depends on the net
effect of total angiogenic stimulation and inhibition occur-
ring in a tumor and other nonangiogenic factors like oxygen
and nutrient consumption rate of the tumor cells.47 Surgery
may disturb this balance by removing the source of angio-
genic inhibition. Therefore microvessel density counting
with CD31/CD34 staining could be done in both patients
who have had biopsies and are coming for definitive surgery
and in patients whose tumors have recurred or relapsed (to
compare these with previous excision biopsies). Cross-
racial comparisons of micro-vessel densities in breast can-
cers resected from premenopausal AA and EA node-positive
women should be done. Also, animal experiments with and
without the administration of preoperative antiangiogenic
agents and assessing microvessel density on the final pa-
thology may be carried out. This will give more histological
tissue for microvessel density assessment than is possible
with core biopsies in patients. We could correlate this
with recurrence and survival of the laboratory animal.
Angiogenesis inhibition
The expressions of angiogenesis inhibitors like thrombo-
spondin-148 in a serial fashion before and after surgery
could be done, to see if surgery really has an effect on their
levels. One shall then compare the magnitude of such an ef-
fect in premenopausal/postmenopausal and black/white
women and relate this to survival and recurrence. It might
be useful to relate findings to the histopathologic and mi-
crovascular pattern of the initial tumor to see if different
tumor types have different potentials for angiogenic
inhibition.
Genetic polymorphism
Genetic polymorphism relating to genes controlling angio-
genesis may be associated with differential effects on
tumor progression and patient survival.17 For example,
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transforming growth factor beta 1(TGFB1) was associated
with differential tissue sensitivity to radiotherapy,49 and
Carey et al.50 reported that a basal-like subtype invasive
breast cancer is more prominent in AA than EA. We could
compare specific angiogenesis related genotypes in the dif-
ferent ethnic populations and survival following surgery for
breast cancer.
Concluding remarks
In conclusion, we suggest that the observed race-related
changes in breast cancer mortality may, in part, stem from
screening and subsequent resection of poor-prognosis
breast cancers among AA premenopausal women, which
negatively impacts the host cancer balance in a subset of
these women. The mammography screening introduction
should be considered as a probe revealing biologic features
of the hostedisease balance in AA and EA, as reflected by
the change in mortality dynamics. This conceptual ap-
proach is analogous to using CMF adjuvant chemotherapy
given after resection as a probe to study the postsurgical
recurrence dynamics, which provide information about the
underlying structure of the recurrence pattern of patients
undergoing surgery alone.51
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